Analytical Data
-
Gene name
Cadherin-13
- Application
-
Alternative Names
Cadherin-13; H-cadherin; T-cadherin; T-cad; CDH13
-
Species
Rat
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8R490
-
Expression Region
A22-A692
-
Protein Length
Partial
-
Molecular Weight
117 kDa & 95 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cadherin-13, also known as T-cadherin, is a member of the cadherin family of proteins, which are critical for cell-cell adhesion processes in various tissues. Unlike classical cadherins, Cadherin-13 is predominantly expressed in the nervous system and has been implicated in neural development, synaptic regulation, and maintenance of neuronal integrity. Research has highlighted its potential role in tumor suppression, as reduced expression of Cadherin-13 has been associated with various cancers, including ovarian and breast cancer. The interest in studying recombinant Cadherin-13 proteins stems from the need to better understand the molecular mechanisms underlying its function and interactions. By producing and characterizing recombinant Cadherin-13, researchers aim to elucidate its structural properties, enabling insights into how it mediates cell adhesion and signaling pathways. Additionally, investigating its interactions with other cellular partners could reveal therapeutic targets for cancer and neurodegenerative diseases. Overall, the study of Cadherin-13 recombinant proteins represents a promising avenue for advancing our understanding of cellular processes and developing novel treatment strategies in oncology and neurology.
